BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sztrymf B, Libert JM, Mougeot C, Lebrec D, Mazmanian M, Humbert M, Herve P. Cirrhotic rats with bacterial translocation have higher incidence and severity of hepatopulmonary syndrome. J Gastroenterol Hepatol. 2005;20:1538-1544. [PMID: 16174071 DOI: 10.1111/j.1440-1746.2005.03914.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Giuffrè M, Campigotto M, Campisciano G, Comar M, Crocè LS. A story of liver and gut microbes: how does the intestinal flora affect liver disease? A review of the literature. Am J Physiol Gastrointest Liver Physiol 2020;318:G889-906. [PMID: 32146836 DOI: 10.1152/ajpgi.00161.2019] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 27.0] [Reference Citation Analysis]
2 Marques TG, Chaib E, da Fonseca JH, Lourenço AC, Silva FD, Ribeiro MA Jr, Galvão FH, D'Albuquerque LA. Review of experimental models for inducing hepatic cirrhosis by bile duct ligation and carbon tetrachloride injection. Acta Cir Bras 2012;27:589-94. [PMID: 22850713 DOI: 10.1590/s0102-86502012000800013] [Cited by in Crossref: 59] [Cited by in F6Publishing: 28] [Article Influence: 7.4] [Reference Citation Analysis]
3 殷云勤, 韩德五, 王新国. 肝硬化大鼠门静脉内毒素水平与Child-Pugh分级之间的关系. 世界华人消化杂志 2006; 14(15): 1471-1474 [DOI: 10.11569/wcjd.v14.i15.1471] [Reference Citation Analysis]
4 Macnaughtan J, Jalan R. Clinical and pathophysiological consequences of alterations in the microbiome in cirrhosis. Am J Gastroenterol. 2015;110:1399-1410; quiz 1411. [PMID: 26416191 DOI: 10.1038/ajg.2015] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Koch DG, Fallon MB. Hepatopulmonary Syndrome. Clinics in Liver Disease 2014;18:407-20. [DOI: 10.1016/j.cld.2014.01.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
6 Surani SR, Mendez Y, Anjum H, Varon J. Pulmonary complications of hepatic diseases. World J Gastroenterol 2016; 22(26): 6008-6015 [PMID: 27468192 DOI: 10.3748/wjg.v22.i26.6008] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
7 Del Valle K, DuBrock HM. Hepatopulmonary Syndrome and Portopulmonary Hypertension: Pulmonary Vascular Complications of Liver Disease. Compr Physiol 2021;11:1-22. [PMID: 34636408 DOI: 10.1002/cphy.c210009] [Reference Citation Analysis]
8 Lv Y, Fan D. Hepatopulmonary Syndrome. Dig Dis Sci. 2015;60:1914-1923. [PMID: 25732713 DOI: 10.1007/s10620-015-3593-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
9 Fan J, Edsen-Moore MR, Turner LE, Cook RT, Legge KL, Waldschmidt TJ, Schlueter AJ. Mechanisms by which chronic ethanol feeding limits the ability of dendritic cells to stimulate T-cell proliferation. Alcohol Clin Exp Res 2011;35:47-59. [PMID: 21039629 DOI: 10.1111/j.1530-0277.2010.01321.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
10 Soulaidopoulos S, Goulis I, Cholongitas E. Pulmonary manifestations of chronic liver disease: a comprehensive review. Ann Gastroenterol 2020;33:237-49. [PMID: 32382226 DOI: 10.20524/aog.2020.0474] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Aller MA, Arias JL, García-Domínguez J, Arias JI, Durán M, Arias J. Experimental obstructive cholestasis: the wound-like inflammatory liver response. Fibrogenesis Tissue Repair. 2008;1:6. [PMID: 19014418 DOI: 10.1186/1755-1536-1-6] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 2.9] [Reference Citation Analysis]
12 Alonso Martínez JL. Síndrome hepatopulmonar: mayoría de edad clínica. Medicina Clínica 2008;130:95-7. [DOI: 10.1157/13115366] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Aller MA, Prieto I, Argudo S, de Vicente F, Santamaría L, de Miguel MP, Arias JL, Arias J. The interstitial lymphatic peritoneal mesothelium axis in portal hypertensive ascites: when in danger, go back to the sea. Int J Inflam. 2010;2010:148689. [PMID: 21152120 DOI: 10.4061/2010/148689] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
14 Grilo-Bensusan I, Pascasio-Acevedo JM. Hepatopulmonary syndrome: What we know and what we would like to know. World J Gastroenterol 2016; 22(25): 5728-5741 [PMID: 27433086 DOI: 10.3748/wjg.v22.i25.5728] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
15 Soulaidopoulos S, Cholongitas E, Giannakoulas G, Vlachou M, Goulis I. Review article: Update on current and emergent data on hepatopulmonary syndrome. World J Gastroenterol 2018; 24(12): 1285-1298 [PMID: 29599604 DOI: 10.3748/wjg.v24.i12.1285] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
16 Cartin-Ceba R, Krowka MJ. Pulmonary Complications of Portal Hypertension. Clin Liver Dis 2019;23:683-711. [PMID: 31563218 DOI: 10.1016/j.cld.2019.06.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
17 Borkar VV, Poddar U, Kapoor A, Ns S, Srivastava A, Yachha SK. Hepatopulmonary Syndrome in children: a comparative study of non-cirrhotic vs. cirrhotic portal hypertension. Liver Int 2015;35:1665-72. [DOI: 10.1111/liv.12708] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 2.9] [Reference Citation Analysis]
18 Raevens S, Geerts A, Paridaens A, Lefere S, Verhelst X, Hoorens A, Van Dorpe J, Maes T, Bracke KR, Casteleyn C, Jonckx B, Horvatits T, Fuhrmann V, Van Vlierberghe H, Van Steenkiste C, Devisscher L, Colle I. Placental growth factor inhibition targets pulmonary angiogenesis and represents a therapy for hepatopulmonary syndrome in mice: Liver Failure/Cirrhosis/Portal Hypertension. Hepatology 2018;68:634-51. [DOI: 10.1002/hep.29579] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
19 Mortensen C, Andersen O, Krag A, Bendtsen F, Møller S. High-sensitivity C-reactive protein levels predict survival and are related to haemodynamics in alcoholic cirrhosis. Eur J Gastroenterol Hepatol. 2012;24:619-626. [PMID: 22441510 DOI: 10.1097/meg.0b013e328351db6e] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
20 Cosarderelioglu C, Cosar AM, Gurakar M, Dagher NN, Gurakar A. Hepatopulmonary Syndrome and Liver Transplantation: A Recent Review of the Literature. J Clin Transl Hepatol 2016;4:47-53. [PMID: 27047772 DOI: 10.14218/JCTH.2015.00044] [Cited by in Crossref: 17] [Cited by in F6Publishing: 3] [Article Influence: 3.4] [Reference Citation Analysis]
21 Gandhi KD, Taweesedt PT, Sharma M, Surani S. Hepatopulmonary syndrome: An update. World J Hepatol 2021; 13(11): 1699-1706 [DOI: 10.4254/wjh.v13.i11.1699] [Reference Citation Analysis]
22 Liu L, Liu N, Zhao Z, Liu J, Feng Y, Jiang H, Han D. TNF-α neutralization improves experimental hepatopulmonary syndrome in rats. Liver Int 2012;32:1018-26. [PMID: 22672643 DOI: 10.1111/j.1478-3231.2012.02821.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
23 Raevens S, Fallon MB. Potential Clinical Targets in Hepatopulmonary Syndrome: Lessons From Experimental Models. Hepatology 2018;68:2016-28. [PMID: 29729196 DOI: 10.1002/hep.30079] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
24 Bouguila J, Rouatbi H, Tej A, Chabchoub I, Trimech B, El Ajmi S, Essoussi A, Boughammoura L. Syndrome hépatopulmonaire : une complication de la maladie de Gaucher de type 1. Revue de Pneumologie Clinique 2012;68:58-62. [DOI: 10.1016/j.pneumo.2011.07.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
25 Thevenot T, Pastor C, Cervoni J, Jacquelinet C, Nguyen-khac E, Richou C, Heyd B, Vanlemmens C, Mantion G, Di Martino V, Cadranel J. Le syndrome hépatopulmonaire. Gastroentérologie Clinique et Biologique 2009;33:565-79. [DOI: 10.1016/j.gcb.2009.03.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
26 Chabot F, Gomez E, Boyer L, Kheir A, Le Pavec J, Sitbon O, Herve P. Hypertension portopulmonaire. Revue des Maladies Respiratoires 2006;23:629-41. [DOI: 10.1016/s0761-8425(06)72078-2] [Cited by in Crossref: 11] [Article Influence: 0.7] [Reference Citation Analysis]
27 Matyas C, Haskó G, Liaudet L, Trojnar E, Pacher P. Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications. Nat Rev Cardiol 2021;18:117-35. [PMID: 32999450 DOI: 10.1038/s41569-020-0433-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
28 Macnaughtan J, Jalan R. Clinical and Pathophysiological Consequences of Alterations in the Microbiome in Cirrhosis. American Journal of Gastroenterology 2015;110:1399-410. [DOI: 10.1038/ajg.2015.313] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
29 Herve P, Le Pavec J, Sztrymf B, Decante B, Savale L, Sitbon O. Pulmonary vascular abnormalities in cirrhosis. Best Pract Res Clin Gastroenterol. 2007;21:141-159. [PMID: 17223502 DOI: 10.1016/j.bpg.2006.07.011] [Cited by in Crossref: 47] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
30 Zhu J, Qiu J, Chen K, Wang W, Zheng S. Tea polyphenols and Levofloxacin alleviate the lung injury of hepatopulmonary syndrome in common bile duct ligation rats through Endotoxin -TNF signaling. Biomed Pharmacother 2021;137:111263. [PMID: 33516071 DOI: 10.1016/j.biopha.2021.111263] [Reference Citation Analysis]
31 Chang CC, Wang SS, Hsieh HG, Lee WS, Chuang CL, Lin HC, Lee FY, Lee SD, Huang HC. Rosuvastatin improves hepatopulmonary syndrome through inhibition of inflammatory angiogenesis of lung. Clin Sci (Lond). 2015;129:449-460. [PMID: 25940601 DOI: 10.1042/cs20140622] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
32 Yi H, An Y, Lv H, Wei X, Yi X, Wang G, Yang Y, Chen G, Yi S. The association of lipopolysaccharide and inflammatory factors with hepatopulmonary syndrome and their changes after orthotopic liver transplantation. J Thorac Dis 2014;6:1469-75. [PMID: 25364524 DOI: 10.3978/j.issn.2072-1439.2014.10.05] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Oswald-Mammosser M, Rashid S, Boehm N, Agin A, Geny B, Schini-Kerth V, Charloux A. Effect of the oestrogen receptor antagonist fulvestrant on the cirrhotic rat lung. Fundam Clin Pharmacol. 2015;29:269-277. [PMID: 25753092 DOI: 10.1111/fcp.12114] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
34 Mandell MS. The diagnosis and treatment of hepatopulmonary syndrome. Clin Liver Dis 2006;10:387-405, x. [PMID: 16971268 DOI: 10.1016/j.cld.2006.05.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]